Pfizer Inc. on Friday said the European Commission has approved the expanded use of Lorviqua as monotherapy for adults with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously not treated with an ALK inhibitor.
The New York drugmaker said the approval is based on results from a Phase 3 study in which Lorviqua reduced risk of disease progression or death by 72% in newly diagnosed individuals compared to the company's Xalkori cancer treatment.
The EC in 2019 granted conditional marketing authorization for Lorviqua as a monotherapy for adults with ALK-positive advanced non-small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor therapy, or crizotinib and at least one other ALK tyrosine kinase inhibitor.
Pfizer markets the drug in the U.S. under the trade name Lorbrena.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.